EVO:NASDAQ
Evotec SE
$1.63
0.00%
(0.00) 1D
$1.63
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 16, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EVO...
Open
$1.64
High
$1.65
Low
$1.61
Mkt. cap
576.24M
Avg. vol.
61.20K
Volume
24.91K
52-wk high
$4.27
52-wk low
$1.60
EPS
-$0.64
Beta
1.92
Shares outstanding
355.82M
No. of employees
4K
Open
$1.64
High
$1.65
Low
$1.61
Mkt. cap
576.24M
Avg. vol.
61.20K
Volume
24.91K
52-wk high
$4.27
52-wk low
$1.60
EPS
-$0.64
Beta
1.92
Shares outstanding
355.82M
No. of employees
4K
News stories
From web sources and news partners
ad-hoc-news.de
·
2 days ago
Evotec stock falls to a new 52-week low as analysts split on 2026 outlook
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE